Results 31 to 40 of about 315,867 (288)
Resistant prolactinoma: Is it monoclonal or polyclonal?
Indian Journal of Endocrinology and Metabolism, 2013 Prolactinomas are solitary benign neoplasms and resistance to dopamine agonists occur in a small percentage of prolactinomas. Multiple pituitary adenomas are reported in less than 1% of pituitary adenomas and rarely result in resistant prolactinoma.
K. V. S. Hari Kumar, Pitambar Prusty
doaj +1 more source
Dopamine Agonists and Pathologic Behaviors [PDF]
Parkinson's Disease, 2012 The dopamine agonists ropinirole and pramipexole exhibit highly specific affinity for the cerebral dopamine D3 receptor. Use of these medications in Parkinson’s disease has been complicated by the emergence of pathologic behavioral patterns such as hypersexuality, pathologic gambling, excessive hobbying, and other circumscribed obsessive-compulsive ...
Brendan J. Kelley +2 more
openaire +3 more sources
Nature and Science of Sleep, 2023 Elliott Kyung Lee,1,2 Naomi Spitale,2,3 Rebecca Robillard2 1Department of Psychiatry, University of Ottawa, Ottawa, Ontario, Canada; 2Sleep Research Unit, Institute for Mental Health Research (IMHR), Ottawa, Ontario, Canada; 3Department of Medicine ...
Lee EK, Spitale N, Robillard R
doaj
Management of prolactinoma during pregnancy and postpartum
Journal of Integrated Health Sciences, 2015 Prolactinoma is classified as microprolactinoma when it measures
Om J Lakhani +3 more
doaj +1 more source
Natural Frequencies of Levodopa‐Induced Dyskinesia in Parkinson's Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objectives Abnormal involuntary movements, known as dyskinesias, are common complications of levodopa treatment in patients with Parkinson's disease and can significantly impair quality of life. The underlying pathophysiology remains unclear, and current therapeutic options are limited.
Ioannis U. Isaias +3 more
wiley +1 more source
Neuropsychopharmacology Reports, 2020 Aims The United States of America is currently in an opioid epidemic. Heroin remains the most lethal opioid option with its death rate increasing by over 500% in the last decade.
Dominic P. Isaacs +5 more
doaj +1 more source
Dopamine receptor subtypes and ingestive behaviour [PDF]
, 1999 Both centrally and systemically administered dopamine agonists and antagonists decrease ingestive behaviour. The aim of this thesis was to examine whether drugs acting at different receptor subtypes decreased intake in different ways.
Genn, Rachel F., Genn, R.F.
core
Pharmacology of novel psychoactive substances [PDF]
, 2016 This PhD work consists of an in vitro and in vivo part. In the in vivo part, we investigated the role of dopamine in the acute clinical effects of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) in healthy human subjects.
Rickli, Anna
core +1 more source
Progressive Parkinsonism in PPP2R5D‐Related Neurodevelopmental Disorder
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT PPP2R5D‐related neurodevelopmental disorder (Houge–Janssens syndrome type 1) is a rare autosomal dominant condition characterized by macrocephaly, intellectual disability, and epilepsy. Progressive parkinsonism is an emerging adult phenotype that neurologists should be aware of since timely genetic diagnosis opens the door to disease‐modifying
Katerina Bernardi +6 more
wiley +1 more source
Individual differences in reward-prediction-error: extraversion and feedback-related negativity [PDF]
, 2010 Medial frontal scalp-recorded negativity occurring ∼200–300 ms post-stimulus [known as feedback-related negativity (FRN)] is attenuated following unpredicted reward and potentiated following unpredicted non-reward.
Smillie, Luke D. +5 more
core +1 more source